Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Nov 25;21(23):8960.
doi: 10.3390/ijms21238960.

A Molecular Perspective on the Potential Benefits of Metformin for the Treatment of Inflammatory Skin Disorders

Affiliations
Review

A Molecular Perspective on the Potential Benefits of Metformin for the Treatment of Inflammatory Skin Disorders

Ji-Eun Chang et al. Int J Mol Sci. .

Abstract

Due to its anti-hyperglycemic effect, metformin is the first-line medication for the treatment of type 2 diabetes, particularly in people who are obese. However, metformin is a drug with a very wide range of pharmacological properties and reports of its therapeutic effect on diseases including inflammation and cancer are increasing. Numerous research groups have reported that metformin has beneficial effects on a variety of inflammatory skin disorders including psoriasis, acanthosis nigricans, acne, hidradenitis suppurativa, and allergic contact dermatitis. According to these reports, in addition to the well-known action of metformin, that is, its anti-hyperglycemic effect, NF-kB inhibition and the resulting alteration to the cytokine network may be the potential targets of metformin. Its anti-hyperandrogenism effect has also been confirmed as the major action of metformin in some inflammatory skin diseases. Moreover, novel regulatory mechanisms, including autophagy and antioxidant processes, have been suggested as promising mechanisms of action for metformin in inflammatory skin disorders.

Keywords: acanthosis nigricans; acne; allergic contact dermatitis; hidradenitis suppurativa; inflammatory skin disorders; metformin; psoriasis.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Similar articles

Cited by

References

    1. He L. Metformin and Systemic Metabolism. Trends Pharmacol. Sci. 2020;41:868–881. doi: 10.1016/j.tips.2020.09.001. - DOI - PMC - PubMed
    1. Viollet B., Guigas B., Sanz Garcia N., Leclerc J., Foretz M., Andreelli F. Cellular and molecular mechanisms of metformin: An overview. Clin. Sci. 2012;122:253–270. doi: 10.1042/CS20110386. - DOI - PMC - PubMed
    1. Deng M., Su D., Xu S., Little P.J., Feng X., Tang L., Shen A. Metformin and Vascular Diseases: A Focused Review on Smooth Muscle Cell Function. Front. Pharmacol. 2020;11:635. doi: 10.3389/fphar.2020.00635. - DOI - PMC - PubMed
    1. Solymár M., Ivic I., Pótó L., Hegyi P., Garami A., Hartmann P., Pétervári E., Czopf L., Hussain A., Gyöngyi Z., et al. Metformin induces significant reduction of body weight, total cholesterol and LDL levels in the elderly—A meta-analysis. PLoS ONE. 2018;13 doi: 10.1371/journal.pone.0207947. - DOI - PMC - PubMed
    1. Del Barco S., Vazquez-Martin A., Cufí S., Oliveras-Ferraros C., Bosch-Barrera J., Joven J., Martin-Castillo B., Menendez J.A. Metformin: Multi-faceted protection against cancer. Oncotarget. 2011;2:896–917. doi: 10.18632/oncotarget.387. - DOI - PMC - PubMed

MeSH terms